Clausen Clara Lundetoft, Egeskov-Cavling Amanda Marie, Hayder Noor, Sejdic Adin, Roed Casper, Gitz Holler Jon, Nielsen Lene, Eiberg Mads Frederik, Rezahosseini Omid, Østergaard Christian, Harboe Zitta Barrella, Fischer Thea K, Benfield Thomas, Lindegaard Birgitte
Center of Research and Disruption of Infectious Diseases (CREDID), Department of Infectious Diseases, Amager and Hvidovre Hospital, Copenhagen, Denmark.
Department of Clinical Research, Copenhagen University Hospital, North Zealand Hospital, Hilleroed, Denmark.
Open Forum Infect Dis. 2024 Sep 20;11(10):ofae513. doi: 10.1093/ofid/ofae513. eCollection 2024 Oct.
Respiratory syncytial virus (RSV) and influenza cause significant health challenges, particularly for individuals with comorbid conditions and older adults. However, information on the clinical manifestations and outcomes of adults hospitalized with RSV in Europe remains limited.
This multicenter observational cohort study of adults hospitalized with RSV or influenza A or B from March 2016 to April 2020 investigated the clinical manifestations, mortality risk factors, and association with 90-day mortality rates by logistic regression analysis after adjustment for covariates.
Of 988 patients hospitalized with either virus, 353 had RSV, 347 had influenza A, and 288 had influenza B infection. Patients with RSV, compared with those with influenza A or B, were more likely to have comorbid conditions (83% for RSV vs 72% for influenza A [ = .03] and 74% for influenza B [ = .001]) or pneumonia (41% vs 29% [ = .03] and 24% [ < .001], respectively). After adjustment for covariates, RSV infection was associated with an increased all-cause mortality rate within 90 days compared with influenza B (odds ratio, 2.16 [95% confidence interval, 1.20-3.87]; = .01) but not influenza A (1.38 [.84-2.29]; = .21). Increasing age and present pneumonia were identified as independent mortality risk factors in patients with RSV.
Older adults hospitalized with RSV infections are at a higher risk of dying within 90 days of hospitalization than patients admitted with influenza B but at a similar risk as those admitted with influenza A, emphasizing the detrimental effects and severity of older patients being infected with RSV. Our findings underscore the need for strategic testing and vaccination approaches to mitigate the impact of RSV among older adults.
呼吸道合胞病毒(RSV)和流感给健康带来重大挑战,尤其是对患有合并症的个体和老年人。然而,欧洲成人RSV住院患者的临床表现和转归信息仍然有限。
这项多中心观察性队列研究纳入了2016年3月至2020年4月因RSV、甲型流感或乙型流感住院的成人,通过对协变量进行调整后的逻辑回归分析,研究了临床表现、死亡风险因素以及与90天死亡率的关联。
在988例因这两种病毒之一住院的患者中,353例感染RSV,347例感染甲型流感,288例感染乙型流感。与甲型或乙型流感患者相比,RSV患者更有可能患有合并症(RSV患者为83%,甲型流感患者为72%[P = 0.03],乙型流感患者为74%[P = 0.001])或肺炎(分别为41%对29%[P = 0.03]和24%[P < 0.001])。在对协变量进行调整后,与乙型流感相比,RSV感染与90天内全因死亡率增加相关(比值比,2.16[95%置信区间,1.20 - 3.87];P = 0.01),但与甲型流感无关(1.38[0.84 - 2.29];P = 0.21)。年龄增加和存在肺炎被确定为RSV患者的独立死亡风险因素。
与乙型流感住院患者相比,RSV感染住院的老年人在住院90天内死亡风险更高,但与甲型流感住院患者风险相似,这凸显了老年患者感染RSV的有害影响和严重性。我们的研究结果强调了采取策略性检测和疫苗接种方法以减轻RSV对老年人影响的必要性。